Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion
Why the study?
In the absence of robust evidence to guide clinical decision-making, the optimal approach to prevent stroke and systemic embolism in haemodialysis patients with AF remains moot.
What is the optimal approach to prevent stroke and systemic embolism in haemodialysis patients with atrial fibrillation?
Population
Haemodialysis patients with AF
Design
Position paper
Authors
Discussion
Loading...
Member takes
Implication
May warrant caution in anticoagulation decisions for haemodialysis patients with atrial fibrillation; leaves open optimal CHA2DS2-VASc thresholds and DOAC dosing.
Structured PICO
What is the optimal approach to prevent stroke and systemic embolism in haemodialysis patients with atrial fibrillation?
P
Population
Haemodialysis (HD) patients with atrial fibrillation (AF)
I
Intervention
Oral anticoagulation (DOACs or VKAs) and left atrial appendage occlusion
O
Outcome
Prevention of stroke and systemic embolism
This position paper suggests DOACs are preferable to VKAs for stroke prevention in haemodialysis patients with AF, and advocates for more restrictive anticoagulation initiation than current guidelines.
Limitations
- Absence of robust evidence to guide clinical decision-making
- It remains unclear whether AF is a true risk factor for embolic stroke in haemodialysis
- CHA2DS2-VASc score does not adequately discriminate dialysis patients deriving a net benefit from those suffering a net harm from OAC
- Left atrial appendage occlusion has not been properly studied in dialysis patients
- Lack of robust evidence to guide clinical decision-making
- CHA2DS2-VASc score does not adequately discriminate net benefit vs harm in dialysis patients
Cite This Study
Vriese et al. (2021) conducted a review in Haemodialysis patients with atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated. Direct oral anticoagulants (DOACs) offer a superior benefit-risk profile compared to vitamin K antagonists in haemodialysis patients with atrial fibrillation.